O
PSNL icon

OrbiMed’s Personalis PSNL Stock Holding History

OrbiMed’s Portfolio PSNL Stock Details PSNL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-483,842
Closed -$5.27M – 157
2019
Q4 		$5.27M Hold
483,842
– – 0.08% 103
2019
Q3 		$7.1M Buy
483,842
+183,842
+61% +$3.48M 0.13% 85
2019
Q2 		$8.14M Buy
+300,000
New +$8.48M 0.13% 95

Other funds holding PSNL

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed's PSNL Position: Q1 2020 in Review

OrbiMed sold out of Personalis (PSNL) in Q1 2020, closing a stake of 483,842 shares — an estimated $5.27M sold.

OrbiMed first reported a position in PSNL in Q2 2019 and held it in 3 quarters. The position peaked at $8.14M in Q2 2019. 67 funds tracked by Wall St. Rank hold PSNL as of Q1 2020.

  • OrbiMed reported no remaining Personalis position as of Q1 2020 after selling out during the quarter.
  • OrbiMed sold 483,842 Personalis shares in Q1 2020, an estimated $5.27M.
  • OrbiMed first reported a position in Personalis in Q2 2019 and held it in 3 quarters.
  • OrbiMed's Personalis position peaked at $8.14M in Q2 2019.
  • 67 funds tracked by Wall St. Rank held Personalis as of Q1 2020.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.